Latest Governance News

Resolution Minerals has expanded its strategic footprint with three new project acquisitions in NSW and Queensland, supported by a $1.55 million capital raise and promising LiDAR exploration results at Drake East.

Nagambie Resources Limited reported a net cash outflow in Q1 2025 amid ongoing exploration spending, supported by a $3 million secured loan facility and plans for a share placement to fund future operations.

Trigg Minerals has solidified its ownership of the Wild Cattle Creek antimony deposit with NSW government approval and confirmed high-grade antimony and tungsten mineralisation beneath the site. The company also expanded its New South Wales footprint through strategic acquisitions of historic gold and antimony projects.

Narryer Metals reports compelling scandium, gallium, and rare earth assay results at its Rocky Gully Project, alongside advancing a titanium-rich heavy mineral sands discovery through its JV with Petratherm at Muckanippie.

Xanadu Mines has transitioned operatorship of its flagship Kharmagtai project to Zijin Mining, delivered key feasibility milestones, and is now exploring strategic funding and corporate options amid a solid cash position.

Gas2Grid Limited moves closer to securing a new service contract in the Philippines while appealing a significant legal claim in France, all under the pressure of an impending ASX suspension deadline.

Silver Mines Limited reports steady progress on its flagship Bowdens Silver Project and initiates diamond drilling at the Elsienora Gold Project, while navigating complex regulatory hurdles in New South Wales.

Aldoro Resources has responded to an ASX price query by releasing partial exploration assay results after a significant share price jump, citing laboratory delays and confidentiality concerns as reasons for prior nondisclosure.

Northern Minerals has made significant progress on its Browns Range Heavy Rare Earths Project, advancing its feasibility study and exploration while raising $41.5 million, positioning itself as a strategic alternative amid growing geopolitical supply risks.

Percheron Therapeutics has discontinued its ATL1103 program and curtailed investment in ATL1102 following underwhelming trial results, while advancing talks to in-license new rare disease therapies and extending its cash runway into FY2027.

Syntara Limited reports significant clinical progress with its lead myelofibrosis drug SNT-5505 and launches a new trial for its next-generation anti-fibrotic skin treatment, supported by a solid $18 million cash reserve.

AustChina Holdings has completed the acquisition of Penwortham Exploration, gaining full control of promising gold-antimony and base metals projects in Tasmania, and has commenced exploration activities in a prolific mining region.